258 related articles for article (PubMed ID: 34124139)
1. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
[No Abstract] [Full Text] [Related]
2. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
[TBL] [Abstract][Full Text] [Related]
4. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Wu YL; Fulgenzi CAM; D'Alessio A; Cheon J; Nishida N; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ; Ang C
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497316
[TBL] [Abstract][Full Text] [Related]
7. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort.
Young S; Cam I; Gencturk M; Rubin N; D'souza D; Flanagan S; Golzarian J; Sanghvi T
J Hepatocell Carcinoma; 2021; 8():1513-1524. PubMed ID: 34881208
[TBL] [Abstract][Full Text] [Related]
9. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Wang C; Wang M; Zhang X; Zhao S; Hu J; Han G; Liu L
Ann Transl Med; 2020 Apr; 8(8):541. PubMed ID: 32411764
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy.
He C; Zhang Y; Cai Z; Lin X
Cancer Manag Res; 2019; 11():1391-1400. PubMed ID: 30863150
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors.
Guo Y; Wu W; Sun B; Guo T; Si K; Zheng C; Li X
Front Oncol; 2024; 14():1293680. PubMed ID: 38322419
[TBL] [Abstract][Full Text] [Related]
12. Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers.
Gulmez A; Harputluoglu H
J Gastrointest Cancer; 2023 Mar; 54(1):11-19. PubMed ID: 35119620
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
[TBL] [Abstract][Full Text] [Related]
14. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
15. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
Park Y; Chang AR
Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Scores: Correlation with Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing Transarterial Radioembolization.
Young S; Rubin N; D'Souza D; Sharma P; Pontolillo J; Flanagan S; Golzarian J; Sanghvi T
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):461-475. PubMed ID: 35178599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
